PHASE 3 STUDY:LOW GRADE LYMPH COMP CYCLOPHOSPHAMIDE/FLUDARABINE TO STD THER FOL

第 3 阶段研究：低级别淋巴组合物环磷酰胺/氟达拉滨至 STD THER FOL

• 批准号: 7378554
• 负责人: CHRISTOPHER EHMANN
• 金额: $ 0.39万
• 依托单位: PENNSYLVANIA STATE UNIV HERSHEY MED CTR
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2007-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7378554
• 关键词: PHASE; STUDY; LOW; GRADE; LYMPH

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to compare the response rate, time to progression and survival for patients with low-grade lymphoma treated with the Cyclophosphamide/Fludarabine regimen with a control arm of standard CVP. The study will also determine the effect of maintenance with anti-CD20 on time to progression and survival and its effect on lymphocytic number, subsets and quantitative immunoglobin levels over time.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子弹和调查员（PI）可能已经从其他NIH来源获得了主要资金，因此可以在其他清晰的条目中代表。列出的机构适用于该中心，这不一定是调查员的机构。这项研究的目的是比较用标准CVP的对照组用环磷酰胺/氟达拉滨治疗的低度淋巴瘤患者的反应率，进展时间和存活时间。该研究还将确定抗CD20的维持的影响，随着时间的推移，其对淋巴细胞数，亚群和定量免疫白蛋白水平的影响及其对淋巴细胞数量的影响。